1. 209 Attainment of low disease activity and remission with atacicept in patients with systemic lupus erythematosus and high disease activity in the phase IIb ADDRESS II study and its long-term extension. (April 2019) Authors: Morand, Eric; T Merrill, Joan; A Isenberg, David; H Kao, Amy; Vazquez-Mateo, Cristina; Wax, Stephen; Chang, Peter; Pudota, Kishore; Aranow, Cynthia; J Wallace, Daniel Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study. Issue 2 (29th January 2018) Authors: Merrill, Joan T.; Wallace, Daniel J.; Wax, Stephen; Kao, Amy; Fraser, Patricia A.; Chang, Peter; Isenberg, David Journal: Arthritis & rheumatology Issue: Volume 70:Issue 2(2018) Page Start: 266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Metopimazine is primarily metabolized by a liver amidase in humans. Issue 1 (17th December 2021) Authors: Busby, Robert W.; Cai, Xiaokun; Yang, Sihyung; Ramos, Luis; Venkatarangan, Lata; Shen, Helen; Wax, Stephen; Sadeque, Abu J. M.; De Colle, Cyril Journal: Pharmacology research & perspectives Issue: Volume 10:Issue 1(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease. (8th June 2018) Authors: Khanna, Dinesh; Tashkin, Donald P; Denton, Christopher P; Lubell, Martin W; Vazquez-Mateo, Cristina; Wax, Stephen Journal: Rheumatology Issue: Volume 58:Number 4(2019) Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Issue 1 (2nd December 2016) Authors: Gordon, Caroline; Wofsy, David; Wax, Stephen; Li, Yong; Pena Rossi, Claudia; Isenberg, David Journal: Arthritis & rheumatology Issue: Volume 69:Issue 1(2017) Page Start: 122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Issue 1 (2nd December 2016) Authors: Gordon, Caroline; Wofsy, David; Wax, Stephen; Li, Yong; Pena Rossi, Claudia; Isenberg, David Journal: Arthritis & rheumatology Issue: Volume 69:Issue 1(2017) Page Start: 122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. (2nd January 2017) Authors: Samy, Eileen; Wax, Stephen; Huard, Bertrand; Hess, Henry; Schneider, Pascal Journal: International reviews of immunology Issue: Volume 36:Number 1(2017) Page Start: 3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗